[PRNewswire] Tigermed Advances Clinical Data Management with Veeva Vault EDC
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are delighted to partner with Veeva, advancing our operations to help sponsors more efficiently manage clinical trials and deliver on their commitments to the industry and patients faster," said Ms. Gu Peili, vice president, head of data management at Tigermed, "In recent years, rapid progress has been made in the digitization of clinical trials and EDC in particular, as there have been profound changes in the overseas markets. As a leading CRO, Tigermed keeps investing in new technology, and adopting Veeva Vault EDC will help us to consistently deliver the best experience to our clients around the globe."
이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
-- Modern EDC streamlines key processes to accelerate study builds and make mid-study amendments with no downtime
SHANGHAI May 30, 2024 /PRNewswire=연합뉴스/ -- Veeva Systems (NYSE: VEEV), the global leader in cloud solutions for the life sciences industry, today announced that Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed") has selected Veeva Vault EDC [https://www.veeva.com/products/vault-edc/ ] as its technology foundation for modern electronic data capture (EDC). With Vault EDC, Tigermed can simplify complex data management for faster study builds and mid-study amendments with zero downtime. The improvements can significantly advance Tigermed's clinical data management for the benefit of its customers and the industry.
"We are delighted to partner with Veeva, advancing our operations to help sponsors more efficiently manage clinical trials and deliver on their commitments to the industry and patients faster," said Ms. Gu Peili, vice president, head of data management at Tigermed, "In recent years, rapid progress has been made in the digitization of clinical trials and EDC in particular, as there have been profound changes in the overseas markets. As a leading CRO, Tigermed keeps investing in new technology, and adopting Veeva Vault EDC will help us to consistently deliver the best experience to our clients around the globe."
Tigermed is a leading provider of integrated research and development solutions for the biopharmaceutical and medical device industry. As EDC plays an important role in today's clinical trials, Tigermed's adoption of Vault EDC will help manage the increasing complexity of trials more efficiently while improving data quality and study execution.
"We're proud to partner with Tigermed and drive faster, more effective trials," said Juliana Lu, senior director, R&D and quality and China country lead at Veeva. "With Veeva Vault EDC, Tigermed can deliver more efficient data management services, including higher data quality, lower costs, and a better user experience for research sites. This can help accelerate the development and launch of new drugs to improve patient health."
Veeva Vault EDC is part of the Veeva Clinical Platform [https://www.veeva.com/products/veeva-clinical-platform/ ], the most complete and connected solution to meet the needs of patients, sites, and sponsors. Eight of the top 20 biopharmas and two of the top six global CROs have standardized on Vault EDC to manage future clinical trials. To learn why more companies are adopting Vault EDC, visit veeva.com/WhySwitchtoVaultEDC.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation [https://www.veeva.com/pbc/ ], Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here [https://www.sec.gov/ix?doc=/Archives/edgar/data/0001393052/000139305224000013/veev-20240131.htm ] (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov [https://www.sec.gov/ ].
Source: Veeva Systems
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- [수능] EBS·입시업계 "국어, 킬러문항 없었다…작년 수능보다 쉬워"(종합) | 연합뉴스
- 尹대통령, APEC·G20 참석차 출국…한동훈 환송(종합) | 연합뉴스
- 李, 김혜경 재판에 "먼지털기 희생제물…죽고싶을 만큼 미안" | 연합뉴스
- '3억으로 100억 사업' 막는다…부동산PF 자기자본 20%로 상향 유도(종합) | 연합뉴스
- 트럼프, 다시 김정은과 협상할까…재소환되는 '하노이 노딜'(종합) | 연합뉴스
- 외환당국 7개월만에 구두개입…"과도한 변동성에 적극 조치"(종합) | 연합뉴스
- [수능] 수험생 태워주고 수험표 찾아주고…경찰 187건 지원 | 연합뉴스
- 美대선 후 첨단산업 패권경쟁 향방은…오늘 연합뉴스 미래경제포럼 | 연합뉴스
- 이재명 선거법 위반 내일 1심 선고…'사법리스크' 첫 시험대 | 연합뉴스
- 野, '김여사 특검법' 수정안으로 與 압박…"처리 협조하라" | 연합뉴스